Establishment of new ovarian and colon carcinoma cell lines: differentiation is only possible by cytokeratin analysis.

Por Möbus, V. J., Moll, R., Gerharz, C. D., Kieback, D. G., Weikel, W., Hoffmann, G., Kreienberg, R.
Publicado em 1994

A germline TaqI restriction fragment length polymorphism in the progesterone receptor gene in ovarian carcinoma.

Por McKenna, N. J., Kieback, D. G., Carney, D. N., Fanning, M., McLinden, J., Headon, D. R.
Publicado em 1995

Tissue and plasma expression of the angiogenic peptide adrenomedullin in breast cancer

Por Oehler, M K, Fischer, D C, Orlowska-Volk, M, Herrle, F, Kieback, D G, Rees, M C P, Bicknell, R
Publicado em 2003

Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations

Por Wang-Gohrke, S, Weikel, W, Risch, H, Vesprini, D, Abrahamson, J, Lerman, C, Godwin, A, Moslehi, R, Olipade, O, Brunet, J-S, Stickeler, E, Kieback, D G, Kreienberg, R, Weber, B, Narod, S A, Runnebaum, I B
Publicado em 1999

Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trial

Por Bartlett, J M S, Brookes, C L, Piper, T, van de Velde, C J H, Stocken, D, Lyttle, N, Hasenburg, A, Quintayo, M A, Kieback, D G, Putter, H, Markopoulos, C, Kranenbarg, E M-K, Mallon, E A, Dirix, L Y, Seynaeve, C, Rea, D W
Publicado em 2013